<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893083</url>
  </required_header>
  <id_info>
    <org_study_id>N23-PD-001</org_study_id>
    <nct_id>NCT04893083</nct_id>
  </id_info>
  <brief_title>A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease</brief_title>
  <official_title>A Multi-center, Non-interventional Phase 0 Study for the Collection of Biospecimens From Patients With Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuron23 Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuron23 Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to collect, analyze and preserve biospecimens from patients with&#xD;
      LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new&#xD;
      treatments and novel biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic Marker</measure>
    <time_frame>1 day</time_frame>
    <description>Test for LRRK2 mutations in Parkinson disease patients; identifying patients with potential genetic modifiers</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>LRRK2 Mutant PD</arm_group_label>
    <description>Patients with a G2019S mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LRRK2 Wild Type PD Low burden</arm_group_label>
    <description>Patients with a low burden of genetic modifiers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LRRK2 Wild Type High burden</arm_group_label>
    <description>Patients with a high burden of genetic modifiers</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, urine, CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's patients will be recruited across this multi-center, global clinical study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female â‰¥40&#xD;
&#xD;
          -  Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria&#xD;
             and modified Hoehn and Yahr Stage I, II, or III in the 'OFF' state;&#xD;
&#xD;
          -  Willing to undergo genetic testing for neurologic genotyping panel; -If being treated&#xD;
             for Parkinson's disease, must have been on a stable dose of anti- Parkinson's disease&#xD;
             medications for a minimum of 30 days prior to Day 1;&#xD;
&#xD;
          -  If taking statins, fibrates, antipsychotic or anticonvulsant medications at Day 1,&#xD;
             must have been on a stable dose for a minimum of 30 days, and are not likely to&#xD;
             require a change in dosage for the remainder of the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any major medical illness or unstable medical condition within 6 months of screening&#xD;
             that, in the opinion of the Investigator or Sponsor, may interfere with the subject's&#xD;
             ability to comply with study procedures or abide by study restrictions.&#xD;
&#xD;
          -  Diagnosis of a significant central nervous system disease other than Parkinson's&#xD;
             disease(eg, Huntington's disease, frontotemporal dementia, multi-infarct dementia,&#xD;
             normal pressure hydrocephalus, multiple system atrophy, progressive supranuclear&#xD;
             palsy, drug- induced parkinsonism, Alzheimer's disease)&#xD;
&#xD;
          -  History of stroke;&#xD;
&#xD;
          -  History of epilepsy or seizure disorder other than febrile seizures as a child, or any&#xD;
             seizure or unexpected loss of consciousness (eg, syncope) within 6 months prior to Day&#xD;
             1;&#xD;
&#xD;
          -  History of traumatic brain injury with residual neurological deficit; -If taking&#xD;
             anti-Parkinson's disease medication(s)and are likely to require a change in anti-&#xD;
             Parkinson's disease medication(s) during the study;&#xD;
&#xD;
          -  Known active infectious disease or active infections within 30 days prior to Day 1;&#xD;
&#xD;
          -  Any vaccination within 21 days prior to Day 1;&#xD;
&#xD;
          -  Currently taking, or planning to take, anti-coagulant medications or antiplatelet&#xD;
             medications during the study;&#xD;
&#xD;
          -  Allergy to Lidocaine (xylocaine) or its derivatives or any other LP contraindications;&#xD;
&#xD;
          -  Any other condition which could interfere with, or the treatment for which might&#xD;
             interfere with, the conduct of the study or which would, in the opinion of the&#xD;
             Investigator, unacceptably increase the subject's risk by participating in the study;&#xD;
             -Any systemic glucocorticoids taken within 14 days prior to Day 1 or non-steroidal&#xD;
             anti- inflammatory drugs taken within 4 days prior to Day 1;&#xD;
&#xD;
          -  Received blood products within 30 days prior to Day 1;&#xD;
&#xD;
          -  Donated blood within 30 days prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>VP of Clinical Operations</last_name>
    <phone>8477693016</phone>
    <email>suresh.dheerendra@neuron23.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evergreen Health</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

